HORIZON EUROPE
Europeo
Specific Challenge:Since their discovery, anti-microbials have played an essential role in the treatment of infectious diseases in humans and farmed animals, whether terrestrial or aquatic, and have enormously improved population health as well as food security and safety. However, with the widespread use of anti-microbials for human and animal health in recent decades, the world is increasingly confronted with the emergence and spread of microbes that resist anti-microbial treatment. Discoveries of new anti-microbials are not keeping up with pace anti-microbial resistance (AMR). AMR is responsible for an estimated 25 000 deaths yearly and over EUR 1.5 billion of healthcare costs and productivity losses in the EU alone. Addressing AMR is a cross-sectorial issue, requiring action by different policy areas, from health to agriculture, aquaculture and environment, from research to users, stakeholders and policy makers. A large proportion of anti-microbials is used in livestock production. Although links between this and resistance on human health are not fully established, agriculture is a main target for action. In line with the EU animal health strategy "prevention is better th... ver más
Specific Challenge:Since their discovery, anti-microbials have played an essential role in the treatment of infectious diseases in humans and farmed animals, whether terrestrial or aquatic, and have enormously improved population health as well as food security and safety. However, with the widespread use of anti-microbials for human and animal health in recent decades, the world is increasingly confronted with the emergence and spread of microbes that resist anti-microbial treatment. Discoveries of new anti-microbials are not keeping up with pace anti-microbial resistance (AMR). AMR is responsible for an estimated 25 000 deaths yearly and over EUR 1.5 billion of healthcare costs and productivity losses in the EU alone. Addressing AMR is a cross-sectorial issue, requiring action by different policy areas, from health to agriculture, aquaculture and environment, from research to users, stakeholders and policy makers. A large proportion of anti-microbials is used in livestock production. Although links between this and resistance on human health are not fully established, agriculture is a main target for action. In line with the EU animal health strategy "prevention is better than cure" alternative strategies to anti-microbials need be developed. Alternatives to antimicrobials may be valuable, although evidence of efficacy in controlled trials is currently very limited.
In 2011, the European Commission came up with a five year action plan to fight against AMR and the new action plan[1] is focussing on three pillars: making the EU a best practice region; boosting research, development and innovation; shaping the global agenda. For the purpose of this topic, the words 'animals' and 'farmers' apply to both terrestrial and aquatic animals.
Scope:A. [2018] Rethinking management of health of farmed animals (RIA)
The activities should include socio-economic and behavioural science to analyse the practices, information and decision systems of farmers, veterinarians and other professionals involved in managing the health of farmed animals with (and without) reduced drug use practices, in order to: identify the reasons why farmers accept or reject health management recommendations (e.g. use vs. non-use of anti-microbials, use of vaccines as a preventive measure); identify levers/incentives for adherence to prudent use principles by veterinarians and farmers; create a basis for predicting the behaviour of stakeholders (breeding organizations; feeding and pharmaceutical industries, governments) involved in health management to estimate the effectiveness of intervention measures; create a basis for assessing resource allocation for health management (disease prevention, monitoring, therapeutic intervention, compensation of losses, etc.). The activities should also develop - and if possible validate - integrative strategies for animal health, to foster minimal use of anti-microbials; from breeding and feeding of farmed animals, to biosecurity, good husbandry practices, animal welfare and farm management. Proposals should address both conventional and organic farming. Proposals should fall under the concept of 'multi-actor approach'[2], involving representatives of farmers, extension services, veterinarians and other professionals as well other animal production stakeholders (e.g. feeding, breeding, pharmaceutical industries), and should involve training activities.
B. [2019] Alternatives to anti-microbials (IA)
Activities shall focus on developing and testing new, efficient and targeted alternatives to anti-microbials in farmed animal production. This could be any type of alternative intervention measures (prophylaxis/prevention or treatment), other than vaccines - such as the modulation of host immunity and/or of microbial flora, feed additives or novel molecules. Basic research on gut microbiome should not be covered under this topic. Proposals should take into account the guidelines, standards and legislation in the field, to facilitate the marketing of the measures the project will identify. Proposals should fall under the concept of 'multi-actor approach[2], involving at least representatives of practitioners (e.g. veterinarians), of the feed/feed additives and pharmaceutical industries.
The selected projects under sub-topics A and B should follow the policies and contribute to the objectives of the STAR-IDAZ international research consortium[4]. International cooperation is recommended.
The proposals under sub-topic A and sub-topic B should liaise with other relevant EU projects and initiatives, in particular JPI AMR[5] and the project selected under topic SFS-36-2017. The projects should take into account the guidelines and standards of relevant EU and international statutory bodies, in particular the European Medicines Agency and the World Organisation for Animal Health.
The Commission considers that proposals requesting a contribution from the EU of up to EUR 6 million, for sub-topic A and for sub-topic B, would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.
Expected Impact:The funded activities will contribute to the fight against anti-microbial resistance arising from farmed animal production. More specifically they will help:
develop options for reducing the use of anti-microbials in farming (scope A); develop alternative intervention measures from technology readiness levels (TRL) 5-6 to TRL 7 (scope B). More generally, the funded activities will contribute to improved animal disease prevention and control, reduced production losses and improved resource-use (scopes A and B).
Cross-cutting Priorities:RRIBlue GrowthInternational cooperationSocio-economic science and humanities
[1]https://ec.europa.eu/health/amr/sites/amr/files/amr_action_plan_2017_en.pdf
[2]See definition of the 'multi-actor approach' in the introduction of this Work Programme part
[3]See definition of the 'multi-actor approach' in the introduction of this Work Programme part
[4]http://www.star-idaz.net/
[5]http://www.jpiamr.eu/
ver menos
Características del consorcio
:
La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Características del Proyecto
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Características de la financiación
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects. See the information in the Online Manual.
2. Eligibility and admissibility conditions: described in Annex B and Annex C of the Work Programme.
Proposal page limits and layout: please refer to Part B of the proposal template in the submission system below.
3. Evaluation:
Evaluation criteria, scoring and thresholds are described in Annex H of the Work Programme.
Submission and evaluation processes are described in the Online Manual.
4. Indicative time for evaluation and grant agreements:
Information on the outcome of evaluation (single-stage call): maximum 5 months from the deadline for submission
Signature of grant agreements: maximum 8 months from the deadline for submission.
Information on the outcome of evaluation (two-stage call):
For stage 1: maximum 3 months from the deadline for submission.
For stage 2: maximum 5 months from the deadline for submission.
Signature of grant agreements: maximum 8 months from the deadline for submission.
5. Proposal templates, evaluation forms and model grant agreements (MGA):
Research and Innovation Action:
Specific provisions and funding rates
... 1. Eligible countries: described in Annex A of the Work Programme.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects. See the information in the Online Manual.
2. Eligibility and admissibility conditions: described in Annex B and Annex C of the Work Programme.
Proposal page limits and layout: please refer to Part B of the proposal template in the submission system below.
3. Evaluation:
Evaluation criteria, scoring and thresholds are described in Annex H of the Work Programme.
Submission and evaluation processes are described in the Online Manual.
4. Indicative time for evaluation and grant agreements:
Information on the outcome of evaluation (single-stage call): maximum 5 months from the deadline for submission
Signature of grant agreements: maximum 8 months from the deadline for submission.
Information on the outcome of evaluation (two-stage call):
For stage 1: maximum 3 months from the deadline for submission.
For stage 2: maximum 5 months from the deadline for submission.
Signature of grant agreements: maximum 8 months from the deadline for submission.
5. Proposal templates, evaluation forms and model grant agreements (MGA):
Research and Innovation Action:
Specific provisions and funding rates
Standard proposal template
Standard evaluation form
General MGA - Multi-Beneficiary
Annotated Grant Agreement
Innovation Action:
Specific provisions and funding rates
Standard proposal template
Standard evaluation form
General MGA - Multi-Beneficiary
Annotated Grant Agreement
6. Additional provisions:
Horizon 2020 budget flexibility
Classified information
Technology readiness levels (TRL) – where a topic description refers to TRL, these definitions apply
Members of consortium are required to conclude a consortium agreement, in principle prior to the signature of the grant agreement.
8. Additional documents:
1. Introduction WP 2018-20
9. Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy WP 2018-20
18. Dissemination, Exploitation and Evaluation WP 2018-20
General annexes to the Work Programme 2018-2020
Legal basis: Horizon 2020 Regulation of Establishment
Legal basis: Horizon 2020 Rules for Participation
Legal basis: Horizon 2020 Specific Programme
7. Open access must be granted to all scientific publications resulting from Horizon 2020 actions.
Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
Open access to research data
The Open Research Data Pilot has been extended to cover all Horizon 2020 topics for which the submission is opened on 26 July 2016 or later. Projects funded under this topic will therefore by default provide open access to the research data they generate, except if they decide to opt-out under the conditions described in Annex L of the Work Programme. Projects can opt-out at any stage, that is both before and after the grant signature.
Note that the evaluation phase proposals will not be evaluated more favourably because they plan to open or share their data, and will not be penalised for opting out.
Open research data sharing applies to the data needed to validate the results presented in scientific publications. Additionally, projects can choose to make other data available open access and need to describe their approach in a Data Management Plan.
Projects need to create a Data Management Plan (DMP), except if they opt-out of making their research data open access. A first version of the DMP must be provided as an early deliverable within six months of the project and should be updated during the project as appropriate. The Commission already provides guidance documents, including a template for DMPs. See the Online Manual.
Eligibility of costs: costs related to data management and data sharing are eligible for reimbursement during the project duration.
The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.
Información adicional de la convocatoria
Otras ventajas
Ayudas Similares
| Abierta
| Próximamente
| Abierta